UNASSIGNED: A total of 241 patients suffering from eiHCC, subjected to TACE-P (147 patients) or TACE-R (94 patients) processes from January 1, 2014, to December 31, 2018, were retrospectively reviewed and included. The propensity score matching (PSM) method was used to reduce selection bias.
UNASSIGNED: The median overall survival (mOS) and progression-free survival (mPFS) of the TACE-P group were similar to those recorded for the TACE-R group (P>0.05) before using the PSM technique. Similar results were obtained post the use of the PSM technique. In the subgroup analysis after PSM, patients with single tumor (dimension: ≤5 cm), who were subjected to TACE-P-based treatment methods, exhibited worse tumor response than patients subjected to TACE-R-based methods (HR: 1.804, 95% CI: 1.083-3.005, P=0.023). Seven adverse events were reported. A statistically significant difference for all grades of adverse events (and grade III or IV adverse events) between the two groups (all P>0.05) was not reported.
UNASSIGNED: The benefits and advantages of using the TACE-P based method was similar was those obtained using the TACE-R in patients with eiHCC, especially for patients with a single large tumor or multiple tumors.
■共有241名患有eiHCC的患者,从2014年1月1日至2018年12月31日接受TACE-P(147例)或TACE-R(94例)治疗的患者进行回顾性审查并纳入。倾向评分匹配(PSM)方法用于减少选择偏倚。
■TACE-P组的中位总生存期(mOS)和无进展生存期(mPFS)与使用PSM技术前的TACE-R组相似(P>0.05)。在使用PSM技术后获得了类似的结果。在PSM后的亚组分析中,单个肿瘤患者(尺寸:≤5cm),他们接受了基于TACE-P的治疗方法,与接受基于TACE-R的方法的患者相比,肿瘤反应较差(HR:1.804,95%CI:1.083-3.005,P=0.023)。报告了7个不良事件。两组之间的所有不良事件(以及III级或IV级不良事件)的统计学差异均无统计学意义(均P>0.05)。
■使用基于TACE-P的方法的益处和优点是相似的,在eiHCC患者中使用TACE-R获得的益处和优点,特别是对于单个大肿瘤或多个肿瘤的患者。